Submissions for variant NM_025137.4(SPG11):c.6950G>A (p.Gly2317Asp)

gnomAD frequency: 0.00009  dbSNP: rs79186522

Total submissions: 7

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Illumina Laboratory Services, Illumina	RCV000472621	SCV000391262	uncertain significance	Hereditary spastic paraplegia 11	2018-01-13	criteria provided, single submitter	clinical testing	This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000472621	SCV000545181	uncertain significance	Hereditary spastic paraplegia 11	2024-01-22	criteria provided, single submitter	clinical testing	This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 2317 of the SPG11 protein (p.Gly2317Asp). This variant is present in population databases (rs79186522, gnomAD 0.01%). This missense change has been observed in individual(s) with amyotrophic lateral sclerosis and/or inherited retinal disorder (PMID: 27790088, 32483926). ClinVar contains an entry for this variant (Variation ID: 316077). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SPG11 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Genome Diagnostics Laboratory, The Hospital for Sick Children	RCV001848655	SCV002105771	uncertain significance	Hereditary spastic paraplegia	2016-12-12	criteria provided, single submitter	clinical testing
Genome-Nilou Lab	RCV002467732	SCV002763496	uncertain significance	Amyotrophic lateral sclerosis type 5		criteria provided, single submitter	clinical testing
Genome-Nilou Lab	RCV002467733	SCV002763507	uncertain significance	Charcot-Marie-Tooth disease axonal type 2X		criteria provided, single submitter	clinical testing
Genome-Nilou Lab	RCV000472621	SCV002763518	uncertain significance	Hereditary spastic paraplegia 11		criteria provided, single submitter	clinical testing
Athena Diagnostics	RCV002472990	SCV002771256	uncertain significance	not provided	2021-11-26	criteria provided, single submitter	clinical testing